XNCRXencor, Inc.Running, no new patients
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Ovarian Cancer · Clear Cell Carcinoma · Endometrial Cancer · Cervical Carcinoma · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 170 (planned)
- Started
- Jul 21, 2022
- Main results expected
- Oct 15, 2025
- Fully finished
- Dec 30, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohorts
Measured over: 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-15, no fading
Raw record changes
- none yet
Trial ID NCT05032040 · record last updated 2025-02-07 · checked 2026-11-09 15:47 UTC